Publications by authors named "S Lipkowitz"
Article Synopsis
- The study focuses on specific clusters of CD8+ T cells, categorized as CD8-NOS2+COX2+ and CD8-NOS2-COX2+, which play a significant role in the immune response to tumors.
- These unique cellular environments affect the spatial structure of CD8+ T cell interactions within tumors and can influence patient outcomes.
- The findings suggest that existing treatments, like NOS inhibitors and NSAIDs, could potentially target these cellular neighborhoods to improve cancer therapy.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potential cancer therapeutic that induces apoptosis in cancer cells while sparing the non-malignant cells in preclinical models. However, its efficacy in clinical trials has been limited, suggesting unknown modulatory mechanisms responsible for the lack of TRAIL activity in patients. Here, we hypothesized that TRAIL treatment elicits transcriptional changes in triple negative breast cancer (TNBC) cells that alter the immune milieu.
View Article and Find Full Text PDFContext.—: The Oncotype DX recurrence score (RS) is a widely used test that provides prognostic information on the likelihood of disease recurrence and predictive information on the benefit of chemotherapy in early-stage, hormone receptor-positive breast cancer. Despite its widespread use, quality assurance of the RS does not receive the same level of scrutiny as other tests, such as human epidermal growth factor receptor 2 (HER2) immunohistochemistry.
View Article and Find Full Text PDFArticle Synopsis
- Immune therapy is becoming a key approach in cancer treatment, particularly for aggressive types like triple negative breast cancer (TNBC), where factors like COX2 limit treatment effectiveness.
- A study revealed that combining radiation with the anti-inflammatory drug indomethacin significantly boosted the immune response, reduced tumor growth, and lowered metastasis in mouse models of TNBC.
- The combination treatment led to better local control of tumors and increased survival rates by enhancing immune activity, suggesting that existing NSAIDs could improve the success of radiation therapy in cancer patients.
The multi-cohort phase 2 trial NCT02203513 was designed to evaluate the clinical activity of the CHK1 inhibitor (CHK1i) prexasertib in patients with breast or ovarian cancer. Here we report the activity of CHK1i in platinum-resistant high-grade serous ovarian carcinoma (HGSOC) with measurable and biopsiable disease (cohort 5), or without biopsiable disease (cohort 6). The primary endpoint was objective response rate (ORR).
View Article and Find Full Text PDF